iiinova — where your digital self keeps evolving

Reposted by Raffaele Colombo

Elizabeth McKenna @elizsmckenna.bsky.social · 26/04/2025

Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...

3154

Raffaele Colombo @raffcolo.bsky.social · 24/12/2024

Sharing for the 🦋 aficionados: A record of 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started). Payload class clearly dominated by topo1i with 55 ADCs. Greater diversity observed for antibody targets, featuring novel TAAs and several bispecific ADCs.

121

Raffaele Colombo @raffcolo.bsky.social · 10/12/2024

ADC (in)stabilities: - Both sacituzumab govitecan (SG) and sacituzumab tirumotecan (sac-TMT) have an unstable carbonate linker (half-life ~24 h) that releases their respective payloads over time - SG has an additional point of instability (thiol-maleimide conjugation) Get ready for #SABCS24

021

Reposted by Raffaele Colombo

Paolo Tarantino, MD @ptarantinomd.bsky.social · 09/12/2024

Small preview from Wednesday’s #SABCS24 session on the future of ADCs Question: what do all these ongoing phase 3 ADC trials have in common? 🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2

0122

Raffaele Colombo @raffcolo.bsky.social · 28/11/2024

ADC trivia: what’s the linker stability of the newly approved (by Chinese NMPA) sacituzumab tirumotecan? 1, 2, 3, 4, 5, 6, 7, or 8? For more info on ADC linker (in)stabilities: aacrjournals.org/cancerdiscov...

021

Raffaele Colombo @raffcolo.bsky.social · 27/11/2024

Sacituzumab tirumotecan (aka sac-TMT aka SKB264/MK-2870) approved in China for patients with advanced or metastatic triple negative breast cancer (TNBC) who have received at least 2 prior therapies. This brings the total number of approved ADCs to 13 worldwide (of which 11 by US FDA)!

162

Reposted by Raffaele Colombo

Paolo Tarantino, MD @ptarantinomd.bsky.social · 23/11/2024

The biparatopic anti-HER2 mAb zanidatamab is now approved for treating HER2+ biliary tract cancer. Zanidatamab simultaneously binds to the trastuzumab- and pertuzumab binding domain of HER2. Phase 3 trial ongoing in pretreated HER2+ MBC, led by Sara Tolaney. www.fda.gov/drugs/resour...

0193

Raffaele Colombo @raffcolo.bsky.social · 21/11/2024

Ziihera approved!! 🎉🎉 www.prnewswire.com/news-release...

041

Raffaele Colombo @raffcolo.bsky.social · 19/11/2024

Upcoming early-phase ADC data at #ASH24 (including two interesting preclinical ADCs) 66th ASH Annual Meeting (December 7-10, 2024), full program: ash.confex.com/ash/2024/web... Note: late-breaking abstracts available online on November 25! #ADC #ADCs

071

Reposted by Raffaele Colombo

Paolo Tarantino, MD @ptarantinomd.bsky.social · 17/11/2024

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!

39534